[Use of the depot estrogen ethinylestradiol sulfate in the therapy of menopausal syndrome].
Ethinylestradiol sulfonate is a newly developed orally effective derivate of ethinylestradiol with depot properties produced by "Jenapharm"-GDR. This depot estrogen has been proved for its usefullness in treating menopausal syndrom. A modified Kupperman-index had been used to check the therapeutic results. The effects concerning the endometrium were examined in postmenopausal women that atrophic character of endometrium had been ensured before. Ethinylestradiol sulfonate was applicated in the following dosages: 0,015 mg/day; 0,25 mg/week; 0,5 mg/week; 1,0 mg/week; 3 mg/month. The treatment with 0,25 mg/week over a period of 4 up to 6 weeks proved to be possible and effective if we take into account the endometrial reaction and the danger of bleeding. After the removal of the uterus higher dosages can be given. Up to a dose of 1 mg/week there were not to be seen subjective side effects. Ethinylestradiol sulfonate was compared with other oral estrogens.
D000368:Aged; D055598:Chemical Phenomena; D002621:Chemistry; D004717:Endometrium / Q000187:drug effects; D004997:Ethinyl Estradiol / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D008593:Menopause / Q000187:drug effects*; D008875:Middle Aged; D013997:Time Factors
D004997:Ethinyl Estradiol
Uber die Einsatzfähigkeit des Depotöstrogens Athinylöstradiolsulfonat zur Behandlung klimakterischer Ausfallserscheinungen